In conclusion, our study identified the activation of astrocytic Nrf2 signaling as a viable therapeutic target in AD by controlling neuroinflammation, particularly through the regulation of C3-STAT signaling in astrocytes. This evidence concerns the gene NFE2L2 and Alzheimer disease.